Rehmann Capital Advisory Group’s Ligand Pharmaceuticals LGND Stock Holding History

Rehmann Capital Advisory Group’s Portfolio LGND Stock Details LGND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-63	Closed	-$4.45K	–	1948
2019 Q2	$4.45K	Sell	63 -3	-5%	-$221	﹤0.01%	1587
2019 Q1	$5.15K	Sell	66 -77	-54%	-$5.83K	﹤0.01%	1527
2018 Q4	$12.1K	Sell	143 -412	-74%	-$43.9K	﹤0.01%	998
2018 Q3	$95K	Sell	555 -8	-1%	-$1.21K	0.01%	599
2018 Q2	$72.7K	Sell	563 -24	-4%	-$2.68K	0.01%	658
2018 Q1	$60K	Buy	+587	New	+$58.1K	0.01%	691

Other funds holding LGND

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

CCMLC

Cardinal Capital Management LLC (Connecticut) Greenwich, Connecticut $365M AUM 18.32% 1-Year Est. Return

CCA

Conestoga Capital Advisors Wayne, Pennsylvania $4.6B AUM 16.08% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

SIMG

Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return

Rehmann Capital Advisory Group's LGND Position: Q3 2019 in Review

Rehmann Capital Advisory Group sold out of Ligand Pharmaceuticals (LGND) in Q3 2019, closing a stake of 63 shares — an estimated $4.45K sold.

Rehmann Capital Advisory Group first reported a position in LGND in Q1 2018 and held it in 6 quarters. The position peaked at $95K in Q3 2018. 275 funds tracked by Wall St. Rank hold LGND as of Q3 2019.

Rehmann Capital Advisory Group reported no remaining Ligand Pharmaceuticals position as of Q3 2019 after selling out during the quarter.
Rehmann Capital Advisory Group sold 63 Ligand Pharmaceuticals shares in Q3 2019, an estimated $4.45K.
Rehmann Capital Advisory Group first reported a position in Ligand Pharmaceuticals in Q1 2018 and held it in 6 quarters.
Rehmann Capital Advisory Group's Ligand Pharmaceuticals position peaked at $95K in Q3 2018.
275 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q3 2019.

Based on Rehmann Capital Advisory Group's 13F filing for Q3 2019, filed 2 Jan 2020.